Tata 1mg Posts Strong FY26 Growth With Revenue Close to ₹3,000 Crore, Losses Decline

India's digital healthcare industry continued its rapid expansion during FY26 as online pharmacy and healthcare platforms benefited from rising consumer adoption, stronger demand for diagnostic services and increasing digital health awareness. Companies operating in the sector are focusing on improving operational efficiency while expanding their service offerings to move closer to profitability amid intense competition.

The online healthcare market has witnessed significant investments over the past few years, with major business groups betting on integrated digital ecosystems that combine e-commerce, healthcare, payments and financial services. The growing acceptance of online medicine delivery and diagnostics has created fresh opportunities for healthtech companies to scale their businesses while improving unit economics.

Tata 1mg, the digital healthcare platform backed by Tata Digital, reported another year of strong revenue growth in FY26. The company recorded consolidated revenue of ₹2,936 crore, up 23% from ₹2,392 crore in FY25, while its consolidated net loss narrowed to ₹287 crore, reflecting continued improvement in operating performance despite ongoing investments in business expansion.

Revenue Crosses ₹2,900 Crore

The company's revenue growth was driven by continued demand across online medicine delivery, healthcare products, diagnostics and digital health services. Tata 1mg Healthcare Solutions Private Limited contributed ₹2,440 crore, while Tata 1mg Technologies Private Limited generated ₹496 crore, taking the combined revenue close to the ₹3,000 crore milestone during FY26.

The platform allows customers to purchase allopathic, ayurvedic and homeopathic medicines, nutrition supplements, vitamins and healthcare products while also providing diagnostic testing and other healthcare services. The latest financial performance highlights the continued growth of India's digital healthcare ecosystem as consumers increasingly rely on online platforms for healthcare needs.

FY26 Financial Highlights

Particular	FY26	FY25	Growth
Revenue	₹2,936 crore	₹2,392 crore	23%
Net Loss	₹287 crore	-	Improved
Revenue from Healthcare Solutions	₹2,440 crore	-	-
Revenue from Technologies	₹496 crore	-	-

Losses Continue to Decline

While revenue continued to grow, the company also reported an improvement in profitability. Tata 1mg Healthcare Solutions reported a loss of ₹310 crore, whereas Tata 1mg Technologies remained profitable with a net profit of ₹23 crore. Together, both entities posted a consolidated net loss of ₹287 crore, indicating steady progress towards improving financial performance.

The narrowing losses suggest that the company is benefiting from higher operating scale while continuing to invest in expanding its healthcare platform. Improving profitability remains a key focus for digital healthcare companies as competition intensifies across online pharmacy and diagnostics.

Balance Sheet Remains Strong

At the end of FY26, the combined Tata 1mg entities reported total assets of ₹2,268 crore, with ₹805 crore held by Tata 1mg Healthcare Solutions and ₹1,463 crore by Tata 1mg Technologies.

Combined liabilities stood at ₹1,601 crore, comprising ₹1,509 crore for Tata 1mg Healthcare Solutions and ₹92 crore for Tata 1mg Technologies. The business reported a combined negative reserves and surplus of ₹167 crore, although Tata 1mg Technologies maintained a positive reserves balance that partially offset accumulated losses at the healthcare solutions business.

Balance Sheet Snapshot

Metric	FY26
Total Assets	₹2,268 crore
Total Liabilities	₹1,601 crore
Combined Reserves & Surplus	-₹167 crore
Healthcare Solutions Assets	₹805 crore
Technologies Assets	₹1,463 crore

Competition Remains Intense

Tata 1mg operates in one of India's most competitive digital healthcare markets, competing with major players including Reliance-backed Netmeds, PharmEasy and Apollo 24/7. The company became part of the Tata Group after Tata Digital acquired a majority stake in 1mg in June 2021 as part of its strategy to build a comprehensive digital consumer ecosystem spanning grocery, healthcare, electronics, financial services and payments.

At the parent company level, Tata Digital reported 12% revenue growth to ₹35,990 crore in FY26 compared with ₹32,188 crore in FY25. However, its consolidated net loss widened to ₹4,974 crore from ₹4,610 crore, while gross merchandise value (GMV) reached ₹46,515 crore during the financial year.

What Investors Should Watch

Investors will closely monitor whether Tata 1mg can sustain its strong revenue growth while further reducing losses in the coming quarters. Expansion of diagnostics, higher customer retention, improved operating efficiencies and continued growth in online medicine sales will remain key drivers as India's digital healthcare market continues to mature.

About Tata 1mg

Tata 1mg is a digital healthcare platform owned by Tata Digital that enables users to order medicines, healthcare products, diagnostics and wellness services online. Since becoming part of the Tata Group in 2021, the company has expanded its healthcare ecosystem and strengthened its position as one of India's leading healthtech platforms.

What was Tata 1mg's revenue in FY26?

Tata 1mg reported consolidated revenue of ₹2,936 crore in FY26, up 23% from ₹2,392 crore in FY25.

How much loss did Tata 1mg report?

The company reported a consolidated net loss of ₹287 crore during FY26.

Who owns Tata 1mg?

Tata 1mg is majority owned by Tata Digital, which acquired a controlling stake in the company in June 2021.

Who are Tata 1mg's competitors?

Its major competitors include Netmeds, PharmEasy and Apollo 24/7.